Abstract: The invention provides assays that identify Huntington's disease and monitor the progression and severity of conditions associated with variant Huntingtin protein (Httn). In particular, the invention provides assays that monitor the severity and progression of Huntington's Disease as well as predict the onset of symptoms. The invention also provides assays for identifying drugs for treating Huntington's disease.

Abstract: The invention provides assays that identify Huntington's disease and monitor the progression and severity of conditions associated with variant Huntingtin protein (Httn). In particular, the invention provides assays that monitor the severity and progression of Huntington's Disease as well as predict the onset of symptoms. The invention also provides assays for identifying drugs for treating Huntington's disease.

Abstract: Contemplated compositions and methods are employed to bind in vitro and in vivo to an ?4?2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with ?4??2 dysfunction.

Abstract: The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain in subjects with mild, or mild-to-moderate Alzheimer's disease.

Abstract: Contemplated compositions and methods are employed to bind in vitro and in vivo to an ?4?2 nicotinic acetylcholine receptor in a highly selective manner. Where such compounds are labeled, compositions and methods employing such compounds can be used for PET and SPECT analysis. Alternatively, and/or additionally contemplated compounds can be used as antagonists, partial agonists or agonists in the treatment of diseases or conditions associated with ?4??2 dysfunction.

Abstract: Methods of assigning quantitative phenotype measurement summary statistics to differential brain image information associated with neuropsychiatric disorders are provided. Summary statistics are correlated to genotype information to identify loci that correlate with differential brain image phenotypes. Methods of identifying modulators of genes at the loci are provided, as well as modulators identified by the methods. Systems for correlating polymorphisms and differential brain image phenotypes, for identifying modulators and for making correlations between differential brain activation phenotypes and genotypes are also providedaf.

Abstract: The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain in subjectes with mild, or mild-to-moderate Alzheimer's disease.